Overview

Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Aims of the multi-center, randomized, treatment-controlled clinical trial are to compare the efficacy of sevelamer hydrochloride to calcium-containing phosphorus binders in reducing the rate of progression of femoral and carotid intimal media thickness (IMT) thickening as measured by B-mode ultrasound in stable maintenance hemodialysis (HD) patients.
Phase:
N/A
Details
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborators:
Genzyme, a Sanofi Company
Wolfson Medical Center
Treatments:
Calcium
Calcium Carbonate
Sevelamer